Trailer Wizards Joins TIP Group
30.12.2019 16:00:00 EET | Business Wire | Press release
TIP Trailer Services, a portfolio company of I Squared Capital and one of the leading trailer leasing, rental, maintenance and repair providers across Europe and Canada, today announces it has completed the acquisition of Trailer Wizards, a leading supplier of trailer rental and leasing services in Canada. This follows the announcement of 4 September 2019 on the signing of the agreement for the acquisition.
Following the acquisition, TIP will integrate Trailer Wizards with its existing Canadian business, Train Trailer Rentals. This puts TIP in a strong position for long-term growth as it further strengthens its position in the Canadian market. The acquisition diversifies both the geographical footprint across Canada with the expansion of operations to new provinces and the service segment with more specialized trailers.
“After the recent acquisition of PEMA in Europe, the acquisition of Trailer Wizards is another key milestone in the growth path of TIP,” said Bob Fast, President and CEO of TIP Trailer Services. “By joining the teams of Trailer Wizards and Train Trailer Rentals, we can provide the best in flexible commercial trailer fleet solutions and pursue growth opportunities for the combined businesses. We intend to invest to develop our longstanding customer relationships with world-class transport, logistics, and retail customers in Canada.”
TIP’s Canadian division will have a combined fleet of over 33,000 trailers, reefers, chassis and flatbed or drop-deck configurations. The combined business will employ over 500 people, including approximately 300 mechanics, throughout almost 30 locations in Canada from Prince Edward Island to British Columbia.
The management of the combined business is working together on an integration plan to allow a smooth transition. Unless communicated otherwise, existing contracts, services, terms and conditions and processes will remain in place at each of the businesses.
About TIP Trailer Services
Founded in 1968, TIP Trailer Services is an equipment service provider specializing in trailer leasing, rental, maintenance and repair, as well as other value-added services to transportation and logistics customers across Europe and Canada. The company has one of the largest and most diverse trailer rental and leasing fleets with over 120,000 units. Headquartered in Amsterdam, TIP has over 2,700 employees and services its customers from 120 locations in 18 countries across Europe and Canada. For more information, please visit: https://www.tipeurope.com
About Trailer Wizards
Founded in 1963, Trailer Wizards is Canada’s largest national commercial trailer rental, leasing, sales, service parts, and storage company. Today, Trailer Wizards has 21 locations spanning Canada coast-to-coast including 14 fully staffed customer care centers. For more information, please visit: https://trailerwizards.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191230005029/en/
Contact information
TIP Europe
Media
Marc Aandeweg
Vice President Sales & Marketing
T +31 (0)20 504 – 1767
M +31 (0)613 114293
E marc.aandeweg@tipeurope.com
Investor Relations
Kapil Sharma
Treasury and Investor Relations Director
T +31 (0)20 504 1677
M +31 (0)621 105358
E kapil.sharma@tipeurope.com
Trailer Wizards
Saroj Motwani
Senior Marketing & Communications Specialist
+1 905 740 3925
saroj.motwani@trailerwizards.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom